Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
Julie N GraffChristopher J HoimesWinald R GerritsenUlka N VaishampayanTony ElliottClara HwangAlbert J Ten TijeAurelius OmlinRaymond S McDermottYves FradetScott T TagawaDeepak KilariCristiano FerrarioHiroji UemuraRobert J JonesSatoshi FukasawaAvivit PeerCuizhen NiuChristian H PoehleinPing QiuLeah SuttnerRonald de WitCharles SchlossJohann S de BonoEmmanuel S AntonarakisPublished in: Prostate cancer and prostatic diseases (2024)
ClinicalTrials.gov, NCT02787005.